Drugs / ABSK043
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04964375 | Aug 2021 → Oct 2022 | neoplasm | Abbisko Therapeutics Co, Ltd | Unknown | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07710612 | Aug 2026 → Dec 2029 expected | non-small cell lung carcinoma | Abbisko Therapeutics Co, Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07164170 | Sep 2025 → Dec 2028 expected | non-small cell lung carcinoma | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07014137 | Sep 2025 → Mar 2027 expected | sarcoma | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 2 | NCT06978933 | Apr 2025 → Dec 2026 expected | hepatocellular carcinoma | RenJi Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06668103 | Nov 2024 → Dec 2027 expected | non-small cell lung carcinoma | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06632262 | Nov 2024 → Nov 2029 expected | gastroesophageal cancer, non-small cell lung carcinoma, urothelial carcinoma | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-06-26 | Abbisko Therapeutics Co, Ltd | Results Abbisko Therapeutics Reports Phase II Data of ABSK061 in Combination with ABSK043 in FGFR2-Positive Advanced GC/GEJC Presented at ASCO 2026 abbisko.com ↗
The study demonstrated a favorable safety profile and promising anti-tumor activity of ABSK061 plus ABSK043, with or without CAPOX, in patients with FGFR2-positive advanced GC/GEJC |
| 2025-12-08 | Abbisko Therapeutics Co, Ltd | Results Abbisko Therapeutics Presents Preliminary Phase II Results of Oral PD-L1 Inhibitor ABSK043 Combined with EGFR Inhibitor Firmonertinib for the Treatment of NSCLC at ESMO Asia 2025 abbisko.com ↗
Data showed that the combination demonstrated favorable safety and tolerability. |
| 2025-08-21 | Abbisko Therapeutics Co, Ltd | Regulatory Abbisko Therapeutics Announces IND Clearance from the CDE for ABSK043 in Combination with Glecirasib from Allist Pharmaceuticals, for the Treatment of NSCLC abbisko.com ↗ |
| 2024-12-06 | Abbisko Therapeutics Co, Ltd | Results ESMO Asia 2024: Oral presentation by Abbisko Therapeutics on updated results from a phase 1 study of ABSK043, an oral PD-L1 inhibitor. abbisko.com ↗
The results of the study show that at 600mg -1000mg BID, ABSK043 demonstrated a favorable safety profile and impressive anti-tumor activity as a single agent. |
| 2022-03-11 | Abbisko Therapeutics Co, Ltd | Results Abbisko Therapeutics Declared Two Next-Generation Precision Oncology Preclinical Candidates and Will Present Multiple Discovery and Translational Research Results at AACR Annual Meeting 2022 abbisko.com ↗
A potent and selective small molecule antagonist of PD-L1 ABSK043 demonstrates significant anti-tumor efficacy in combination with other agents in preclinical models |
| 2021-07-12 | Abbisko Therapeutics Co, Ltd | Regulatory Abbisko Therapeutics Obtained Clinical Trial Approval for ABSK043 in Australia abbisko.com ↗
We are very happy to obtain the regulatory approval of ABSK043 in Australia, which is a critical first step for our following clinical trials. |
All press releases naming this drug 15 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABSK043 | “ABSK043, is an orally available, selective and potent inhibitor targeting the interaction of PD-1 and PD-L1” NCT06978933 ↗ |
| Action | Inhibit | “ABSK043 is a novel, oral small molecule inhibitor of PD-L1” NCT04964375 ↗ |
| Modality | Small molecule | “ABSK043 is a novel, oral small molecule inhibitor of PD-L1” NCT04964375 ↗ |
| Route | Oral | “For the Dose Expansion Phase, patients will each receive orally administered doses of ABSK043” NCT04964375 ↗ |